BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai JMT-Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai JMT-Bio's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06380348-2224@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Becotatug: Phase 3 readout est. (NCT06380348)
DESCRIPTION:Becotatug\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JMT10
 1 in Combination With Osimertinib\, Versus Cisplatin-pemetrexed in Partici
 pants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCL
 C) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mu
 tations\nEstimated primary completion: 26 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134205-2224@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Becotatug: Phase 3 readout est. (NCT07134205)
DESCRIPTION:Becotatug\, phase 3\, Colorectal Cancer.\nStudy: The Study of J
 MT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Co
 lorectal Cancer\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07134205
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2751@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SYS6090: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:SYS6090\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SYS60
 90 Combination Therapy in Advanced Lung Cancer\nEstimated primary completi
 on: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sys6090#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07472647
URL:https://assetmemo.bio/drug/sys6090#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
